Clinical features and treatment approaches in cystic fibrosis with pseudo-Bartter syndrome

Ebru Yalçin1, Nural Kiper, Deniz Doğru

  • 1Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey. ebruy@hacettepe.edu.tr

Insights

Cystic fibrosis (CF) infants can develop pseudo-Bartter syndrome (PB), a condition causing dehydration and metabolic alkalosis. Early recognition of symptoms like vomiting and loss of appetite is crucial for timely treatment and preventing complications.

Area of Science:

  • Pediatrics
  • Nephrology
  • Genetics

Background:

  • Infants with cystic fibrosis (CF) are susceptible to pseudo-Bartter syndrome (PB), characterized by hyponatremic, hypochloremic dehydration and metabolic alkalosis.
  • PB in CF infants presents with specific biochemical hallmarks requiring careful diagnostic consideration.

Purpose of the Study:

  • To review the clinical and laboratory features of CF patients diagnosed with PB.
  • To analyze treatment approaches and outcomes for children with CF and PB.

Main Methods:

  • Retrospective review of 29 children with CF and PB from May 1992 to November 2003.
  • Analysis of clinical presentations, laboratory findings, and management strategies.

Main Results:

  • PB was detected in 12% (29/241) of CF patients, with a median age of 4 months at the first episode.
  • Common symptoms included vomiting, loss of appetite, and dehydration; all patients received intravenous fluids and sodium chloride.
  • 12 out of 29 patients required hospitalization for recurrent PB attacks, with the last attack occurring by 48 months of age.

Conclusions:

  • Cystic fibrosis should be considered in the differential diagnosis of metabolic alkalosis in young children.
  • Vomiting and loss of appetite are key warning signs for PB in CF patients, especially before age 4.
  • Early recognition of PB by parents and physicians is vital for preventing severe complications.
Abstract

Related Concept Videos

Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Barrett Esophagus-II: Clinical Manifestations and Management01:21

Barrett Esophagus-II: Clinical Manifestations and Management

Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure entails...